For example, a retrospective analysis of outcomes in an oncology trial for glioblastoma—which tested efficacy of different temozolomide regiments—found that updating the clustering model to incorporate MGMT protein expression and c-MET protein abundance provided better separation of overall survival prognostic groups than incorporating MGMT promoter methylation alone [43]. Here, MGMT is linked to glioblastoma.